Gene Therapy Market Opportunity and Forecast Assessment to Reveal Lucrative Growth Prospects for Key

The Gene Therapy Market accounted for $ 584 million in 2016, reaching $ 4,402 million by 2023, and is estimated to register 33.3% CAGR from 2017 to 2023. North America is the best contributor to the 2016 gene therapy market. However, the Asia Pacific region is expected to grow at the highest rate during the forecast period.

Gene therapy is a promising treatment that can be applied to a wide range of diseases. Their purpose is not only to relieve symptoms but also to fundamentally treat the cause of the disease. They are effective for a wide range of previously untreated diseases such as blood diseases, eye diseases, neurodegenerative diseases, and some cancers. For example, the adeno-associated AAV2 vector carrying a therapeutic gene (RPE65) intraretinal injection improved the vision of people with reverse congenital cataract. Gene therapy can be applied in combination with cellular products in an ex vivo treatment mode (eg Strimvelis) or administered directly in vitro (eg Glybera). Some vectors have clinically relevant options, such as adenovirus (AV), adeno-associated virus (AAV), and lentivirus.

Download PDF Report Sample with statistical info @ https://www.alliedmarketresearch.com/request-sample/2841

The increase in funding for R&D activities pertaining to gene therapy and increase in awareness regarding gene therapy are the major factors that drive the market growth. In addition, increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in prevalence of cancer can fuel the growth of the gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to hamper the market growth.

Among the vector type, viral vectors contribute to the largest share in 2016, and estimated to retain the same trend during the forecast period. Non-viral vector is anticipated to be a lucrative market due to the technological advancement of these vectors with positive results for these therapies during the preclinical and clinical trials for the treatment of various diseases.

Among the gene type, antigen dominates the overall market accounting for two-ninths of the total share in 2016. Among the applications, oncological disorders is the largest contributor towards the market growth.

In 2016, North America accounted for maximum contribution to the total revenue generated, owing to the high prevalence rate of cancer, presence of high disposable income, and high funding for R&D activities associated with gene therapy. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, attributable to rise in incidence rate of cancer, increase in government initiative to improve healthcare infrastructure, and rise in healthcare expenditure.

Key Findings of the Gene Therapy Market:

• Non-viral vectors is projected to grow at the highest rate during the analysis period.
• Oncological disorders segment generated the highest revenue, and is expected to continue its dominance in future.
• North America dominated global gene therapy market in 2016, and is projected to continue its dominance in future.
• China is expected to grow highest in the Asia-Pacific region during the forecast period.
• Antigen was the largest contributor among the gene type segments.

The key companies profiled in the report include

• Novartis
• Kite PharmaInc.
• GlaxoSmithKline PLC
• Spark Therapeutics Inc.
• Bluebird bio Inc.
• Genethon
• Transgene SA
• Applied Genetic Technologies Corporation
• Oxford BioMedica
• NewLink Genetics Corp.

Other prominent players in the value chain include Amgen, Epeius Biotechnologies, Abeona Therapeutics, Sanofi, UniQure, Juno Therapeutics, Adaptimmune, Celgene, and Advantagene.

Make an Enquiry for Promocode Of Discounted Price: @ https://www.alliedmarketresearch.com/purchase-enquiry/2841

Sunny Yadav is a blogger with a strong passion and enjoys writing on miscellaneous domains, as he believes it lets her explore a wide variety of niches. He has an innate interest in creativity and enjoys experimenting with different writing styles.